AAPG 6-K
Ascentage Pharma Group International (AAPG)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of August 2025
Commission File Number: 001-42484
ASCENTAGE PHARMA GROUP INTERNATIONAL
(Translation of Registrant’s name into English)
68 Xinqing Road
Suzhou Industrial Park
Suzhou, Jiangsu
China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On August 8, 2025, Ascentage Pharma Group International posted an announcement on the Hong Kong Stock Exchange entitled, “Notice of Board Meeting”. A copy of the announcement is furnished as Exhibit 99.1 to this Report.
1
INDEX TO EXHIBITS
| Exhibit Number | Exhibit Title |
|---|---|
| 99.1 | Announcement dated August 8, 2025 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ASCENTAGE PHARMA GROUP INTERNATIONAL | |
|---|---|
| Date: August 8, 2025 | /s/ Dajun Yang |
| Name: Dajun Yang | |
| Title: Chief Executive Officer |
3
Exhibit 99.1
HongKong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arisingfrom or in reliance upon the whole or any part of the contents of this announcement.
ASCENTAGE PHARMA GROUP INTERNATIONAL
亞盛醫藥集團
(Incorporated in theCayman Islands with limited liability)
(Stock Code: 6855)
NOTICE OFBOARD MEETING
The board of directors (the “Board”) of Ascentage Pharma Group International (the “Company”, together with its subsidiaries, collectively the “Group”) hereby announces that a meeting of the Board will be held on Wednesday, August 20, 2025, for the purpose of, among other things, considering and, if appropriate, approving the unaudited interim results of the Group for the six months ended June 30, 2025 and its publication.
By order of the Board
Ascentage PharmaGroup International Dr. Yang Dajun
Chairman andExecutive Director
Suzhou, People’s Republic of China, August 8, 2025
Asat the date of this announcement, the Board comprises Dr. Yang Dajun as chairman and executive Director, Dr. Wang Shaomeng and Dr. LuSimon Dazhong as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky, Ms. Marina S. Bozilenko, Dr. DebraYu and Marc E. Lippman, MD as independent non-executive Directors.